Tagged with ARM

R&D-based Pharmaceutical Association Committe You have a long experience in the Chinese pharmaceutical market, and in particular you saw it evolve tremendously over the last 10 years. From a management perspective, would you say that it is easier or harder to tackle today or a decade ago? In my view, the Chinese market is…

PMG Pharma How has your previous professional experience enriched you to run PMG today? And what would you say have been the main milestones and achievements of PMG Pharma since its creation? I should start by mentioning that my professional background starts with a long term experience in a multinational company –…

Asociacion Industrial de Laboratorios Farmace You have previous experience working for innovative pharmaceutical companies such as Procter and Gamble, and today you are the Executive Director for ASILFA. What was your rationale behind making this change? My time at P&G was an excellent experience from which I learned a lot and developed a great network…

Novartis Farmaceutica S.A. de C.V. (Mexico) Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”. Can you tell us how Novartis Mexico fits in with that growth strategy? Mexico is the second biggest market in…

Association of the Russian Pharmaceutical Manufacturers (ARPM) The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization was originally founded as a unifying force amongst Russian national manufacturers, and has now grown to encompass several foreign members.…

Association of International Pharmaceutical Manufactures (AIPM) When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite similar to yours: he had been an administrator and head of the regulatory authority; he subsequently left the administration and…

Astellas Pharma India Pvt. Ltd. When Astellas announced to expand its presence in India in 2009, you were already speaking of the company’s long commitment and solid relationship with India. Can you elaborate on these historical ties and how important it was to set up your India operations at that time? Since the former Fujisawa…

Actelion Pharmaceuticals Founded in 1997 Actelion is certainly the “new kid on the block” when compared to some of the much older mainstays in the pharmaceutical industry. What would you say was the fresh face and the different image that Actelion brought to the industry 13 years ago? The Dutch affiliate started…

ACP PHARMA The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in Poland for over ten years. From the beginning, Mediq NV looked for tenders in Poland, and bought a few companies…

Alphapharm Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a handful of products and a handful of people. Twenty-five years later, we celebrated our silver anniversary, coming from nowhere to…

Pharmaceutical Industry Council (PIC) 2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC). Would you please introduce the organization, and tell us about the main milestones and achievements since you began your tenure…

UTI Pharma South Africa We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head of a much bigger company. To what extent has the distributor now taken a new dimension in terms of financials,…